Eli Lilly Lebanon Adds $4.5B, API Factory Will Be the Largest in U.S. History

On Wednesday, Lilly announced an additional $4.5 billion across two sites at the LEAP Innovation and Research District in Boone County. The first site is an active pharmaceutical ingredient factory set to open next year. The additional investment brings new process designs and the capability to produce Fondayo, Lilly's first once-daily weight loss pill, alongside injectable medications Zepbound and Mounjaro, and Retatratide, a triple hormone receptor agonist in late-stage development. CEO David Ricks put it plainly: it will be the largest API production site in U.S. history. The second site, the Advanced Therapies Facility focused on genetic-level medicine production, opened this week. Combined with a third LEAP facility, the Medicine Foundry, an R&D manufacturing center opening next year, Lilly is running a multi-facility advanced manufacturing corridor through at least 2027, alongside existing LEAP tenants Cummins, Elanco, Corteva, and Roche.

For Indiana manufacturers, the question is not whether this is a large investment. The question is whether your firm is positioned to compete for any of the subcontracting, component supply, construction, or facility services work tied to this build-out. The API factory opens next year, which means procurement and supplier qualification cycles for that facility are active now or will be very soon. If you're in construction, industrial equipment, skilled trades, specialty materials, or logistics in central Indiana and you do not have an active relationship with Lilly's procurement or facilities teams at LEAP, that is the gap to close.